Prognostic biomarker SGSM1 and its correlation with immune infiltration in gliomas

[1] Brat D(2015)Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas N Engl J Med 372 2481-2498

[2] Verhaak R(2016)Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma Cell 164 550-563

[3] Aldape K(2022)Glioma targeted therapy: insight into future of molecular approaches Mol Cancer 21 39-iii105

[4] Yung W(2021)CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2014–2018 Neuro-oncology 23 iii1-1251

[5] Salama S(2021)The 2021 WHO classification of tumors of the central nervous system: a summary Neuro Oncol 23 1231-468

[6] Cooper L(2015)Mutational landscape and clonal architecture in grade II and III gliomas Nat Genet 47 458-273

[7] Rheinbay E(2016)CGCG clinical practice guidelines for the management of adult diffuse gliomas Cancer Lett 375 263-77

[8] Miller C(2020)SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: a study based on TCGA data Int immunopharmacol 84 106490-e8394

[9] Vitucci M(2021)DNA methylation-driven genes for developing survival nomogram for low-grade glioma Front Oncol 11 629521-260

[10] Morozova O(2018)Prognostic relevance of genetic alterations in diffuse lower-grade gliomas Neuro Oncol 20 66-759

[1] Brat D(2015)Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas N Engl J Med 372 2481-2498

[2] Verhaak R(2016)Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma Cell 164 550-563

[3] Aldape K(2022)Glioma targeted therapy: insight into future of molecular approaches Mol Cancer 21 39-iii105

[4] Yung W(2021)CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2014–2018 Neuro-oncology 23 iii1-1251

[5] Salama S(2021)The 2021 WHO classification of tumors of the central nervous system: a summary Neuro Oncol 23 1231-468

[6] Cooper L(2015)Mutational landscape and clonal architecture in grade II and III gliomas Nat Genet 47 458-273

[7] Rheinbay E(2016)CGCG clinical practice guidelines for the management of adult diffuse gliomas Cancer Lett 375 263-77

[8] Miller C(2020)SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: a study based on TCGA data Int immunopharmacol 84 106490-e8394

[9] Vitucci M(2021)DNA methylation-driven genes for developing survival nomogram for low-grade glioma Front Oncol 11 629521-260

[10] Morozova O(2018)Prognostic relevance of genetic alterations in diffuse lower-grade gliomas Neuro Oncol 20 66-759